Cue Biopharma Q3 2023 Earnings Report

Cue Biopharma EPS Results

• Actual EPS: -$0.24
• Consensus EPS: -$0.30
• Beat/Miss: Beat by +$0.06
• One Year Ago EPS: N/A

Cue Biopharma Revenue Results

• Actual Revenue: $2.10 million
• Expected Revenue: $1.49 million
• Beat/Miss: Beat by +$610.00 thousand
• YoY Revenue Growth: N/A

Cue Biopharma Announcement Details

• Quarter: Q3 2023
• Date: 11/9/2023
• Time: N/A

Cue Biopharma (NASDAQ:CUE), a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.